Company intelligence / Profile preview

Concentric Analgesics, Inc.

San Francisco, California, United States

Ownership: Private
Development stage: Phase 3

Overview

Vocacapsaicin (CA-008) has shown positive results in Phase 2 clinical trials for postsurgical pain, demonstrating efficacy over 96 hours in patients undergoing bunionectomy. It has received both Fast Track Designation (2017) and Breakthrough Therapy Designation (2018) from the FDA.

Therapeutic areas: NeurologyRheumatology
Modalities: Small moleculesprodrugs
Industry: Biotech

Drug pipeline

3 assets

vocacapsaicin

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Concentric Analgesics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concentric Analgesics, Inc..

Explore the full profile